3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
281
Carcinoma, Non-Small-Cell Lung
251
Leukemia, Myeloid, Acute
189
Breast Neoplasms
151
Melanoma
150
Neoplasm Metastasis
148
Multiple Myeloma
127
Recurrence
123
Colorectal Neoplasms
119
Lymphoma, Non-Hodgkin
113
Lymphoma
112
Leukemia, Lymphocytic, Chronic, B-Cell
107
Pancreatic Neoplasms
99
Ovarian Neoplasms
99
Precursor Cell Lymphoblastic Leukemia-Lymphoma
91
Leukemia
85
Prostatic Neoplasms
83
Lung Neoplasms
81
Lymphoma, Large B-Cell, Diffuse
77
Squamous Cell Carcinoma of Head and Neck
76
Glioblastoma
73
Carcinoma, Renal Cell
72
Myelodysplastic Syndromes
67
Lymphoma, Follicular
65
Brain Neoplasms
60
Lymphoma, Mantle-Cell
55
Sarcoma
53
Stomach Neoplasms
52
Head and Neck Neoplasms
52
Triple Negative Breast Neoplasms
49
Interventions
pembrolizumab
1
bemarituzumab
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Terminated
×
Squamous-Cell Non-Small-Cell Lung Cancer
×
Clear all
NCT05267470
2025-03-25
FORTITUDE-201
Amgen
Phase 1
Terminated
74 enrolled
22 charts